Biosidus расширяет мощности по производству биопрепаратов и укрепляет глобальные возможности поставок агалсидазы бета

agalsidasae betaPositive

AI Analysis

Summary

Biosidus, an Argentine biotech company with 40+ years of biosimilar development experience, announced expansion of its bioreactor manufacturing facility to strengthen global supply capabilities for agalsidase beta.

Importance:3/10

Sentiment:

0.60

manufacturing expansionbiopharmaceuticalbiosimilarcapacity expansionsupply chain

Read the original article

Published by PR Newswire Clinical Trials on August 27, 2026 6:10 AM

Read Original